Payment overview · 2025
General Payments
$3,255.17
49 reported records · 11 companies
Healthcare provider profile · identity verified
Karina Vila-Rivera, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · SAN JUAN, PR · NPI 1497952584
Verified facts
What the public records show
CMS Open Payments records show Karina Vila-Rivera, M.D. received $3,255.17 in general payments during 2025 across 49 reported records.
Takeda Pharmaceuticals U.S.A., Inc. accounted for 56.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Benlysta, Enbrel, Orencia, Otezla, Ozempic, Rinvoq, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Enbrel by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Prolia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORENCIA as an associated drug or biological on 10404 records involving 2463 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Orencia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Benlysta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $1,841.45 | 56.6% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $534.80 | 16.4% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $253.47 | 7.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $214.37 | 6.6% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $141.44 | 4.3% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $113.10 | 3.5% | 6 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $84.99 | 2.6% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $24.08 | 0.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.47 | 0.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.55 | 0.5% | 1 | 2025 |
| PBG PUERTO RICO LLC | Unresolved — no canonical attribution shown | $14.45 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,778.67 | 42 |
| Travel and Lodging | $1,391.51 | 6 |
| Education | $84.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $299.56 | 6 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $253.47 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $166.56 | 4 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $141.44 | 2 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $122.53 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $113.10 | 6 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $95.24 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $95.24 | 6 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $91.84 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $86.20 | 5 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $84.99 | 1 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| RENFLEXIS Normalized: renflexis |
Drug | Organon LLC | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| AMJEVITA Normalized: amjevita |
Biological | Amgen Inc. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PBG PUERTO RICO LLC | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PBG PUERTO RICO LLC | $14.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ENBREL enbrel |
2025 | Enbrel | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ORENCIA orencia |
2025 | Orencia | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 157 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
157 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
97 | 24 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
54 | 35 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ORENCIA open payments reported associated product |
CMS Open Payments — General Payments 10404 supporting records · 2463 recipient NPIs · example record 1184378623 |
Orencia · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Methotrexate | Methotrexate Sodium | 662 | 102 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 546 | 95 |
| Gabapentin | Gabapentin | 502 | 80 |
| Duloxetine Hcl | Duloxetine Hcl | 285 | 56 |
| Prednisone | Prednisone | 245 | 51 |
| Pregabalin | Pregabalin | 245 | 38 |
| Humira(Cf) Pen | Adalimumab | 164 | 16 |
| Rinvoq | Upadacitinib | 157 | 18 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 127 | 21 |
| Diclofenac Sodium Er | Diclofenac Sodium | 125 | 31 |
| Allopurinol | Allopurinol | 103 | 15 |
| Synthroid | Levothyroxine Sodium | 97 | 24 |
| Xeljanz Xr | Tofacitinib Citrate | 97 | 12 |
| Nabumetone | Nabumetone | 96 | 33 |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 92 | 37 |
| Orencia Clickject | Abatacept | 82 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 80 | 12 |
| Diclofenac Potassium | Diclofenac Potassium | 80 | 29 |
| Enbrel Sureclick | Etanercept | 80 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 78 | 16 |
| Trulicity | Dulaglutide | 78 | 11 |
| Metformin Hcl | Metformin Hcl | 76 | 18 |
| Methylprednisolone | Methylprednisolone | 70 | 46 |
| Colchicine | Colchicine | 65 | 16 |
| Omeprazole | Omeprazole | 61 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 60 | 22 |
| Ibandronate Sodium | Ibandronate Sodium | 60 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 60 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | suppressed |
| Famotidine | Famotidine | 58 | 15 |
| Rybelsus | Semaglutide | 56 | suppressed |
| Benlysta | Belimumab | 54 | suppressed |
| Prolia | Denosumab | 54 | 35 |
| Mounjaro | Tirzepatide | 52 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 49 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 49 | 13 |
| Losartan Potassium | Losartan Potassium | 46 | 11 |
| Sulfasalazine | Sulfasalazine | 45 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 45 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 41 | suppressed |
| Azathioprine | Azathioprine | 41 | suppressed |
| Leflunomide | Leflunomide | 39 | suppressed |
| Ozempic | Semaglutide | 36 | suppressed |
| Sulindac | Sulindac | 36 | 12 |
| Savella | Milnacipran Hcl | 33 | suppressed |
| Meloxicam | Meloxicam | 30 | suppressed |
| Folic Acid | Folic Acid | 28 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Otezla | Apremilast | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Simvastatin | Simvastatin | 25 | suppressed |
| Humira Pen | Adalimumab | 22 | suppressed |
| Orencia | Abatacept | 22 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | 11 |
| Amjevita(Cf) Autoinjector | Adalimumab-Atto | 20 | suppressed |
| Azithromycin | Azithromycin | 20 | 14 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 20 | suppressed |
| Lisinopril | Lisinopril | 20 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Progesterone | Progesterone, Micronized | 18 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Etodolac | Etodolac | 16 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Orphenadrine Citrate | Orphenadrine Citrate | 15 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Desonide | Desonide | 14 | suppressed |
| Olumiant | Baricitinib | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Enbrel | Etanercept | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,255.17 · 49 records | Takeda Pharmaceuticals U.S.A., Inc. | ACTHAR, AMJEVITA, BENLYSTA, ENBREL, EVENITY, HADLIMA, KRYSTEXXA, OCTAGAM IMMUNE GLOBULIN (HUMAN), ORENCIA, OTEZLA, Ozempic, PANZYGA, PURIFIED CORTROPHIN GEL, RENFLEXIS, RINVOQ, Rybelsus, SAPHNELO, SKYRIZI, TAVNEOS | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Benlysta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error